{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:27:43Z","timestamp":1780453663387,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated the triplet regimen obinutuzumab-atezolizumab-lenalidomide (G-atezo-len) for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) in an open-label, multicenter phase Ib\/II study (BO29562; NCT02631577). An initial 3\u2009+\u20093 dose\u2010escalation phase to define the recommended phase II dose of lenalidomide was followed by an expansion phase with G-atezo-len induction and maintenance. At final analysis, 38 patients (lenalidomide 15\u2009mg, <jats:italic>n<\/jats:italic>\u2009=\u20094; 20\u2009mg, <jats:italic>n<\/jats:italic>\u2009=\u200934) had completed the trial. Complete response rate for the efficacy population (lenalidomide 20\u2009mg, <jats:italic>n<\/jats:italic>\u2009=\u200932) at end-of-induction was 71.9% (66.7% in double\u2010refractory patients [refractory to rituximab and alkylator] [<jats:italic>n<\/jats:italic>\u2009=\u200912]; 50.0% in patients with progressive disease within 24 months of first-line therapy [<jats:italic>n<\/jats:italic>\u2009=\u200912]). The 36-month progression-free survival rate was 68.4%. All treated patients had \u22651 adverse event (AE; grade 3\u20135 AE, 32 patients [84%]; serious AE, 18 patients [47%]; AEs leading to discontinuation of any study drug, 11 patients [29%]). There were 2 fatal AEs (1 merkel carcinoma, 1 sarcomatoid carcinoma; both unrelated to any study drug). The G\u2010atezo-len regimen is effective and tolerable in patients with R\/R FL. AEs were consistent with the known safety profile of the individual drugs.<\/jats:p>","DOI":"10.1038\/s41408-021-00539-8","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T11:03:31Z","timestamp":1629457411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: final analysis of a Phase Ib\/II trial"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Katakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"McCord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"539_CR1","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines: Non-Hodgkin\u2019s lymphoma, version 3; 2016."},{"key":"539_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol. 2018;93:296\u2013305.","journal-title":"Am J Hematol."},{"key":"539_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/annonc\/mdw026","volume":"27","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016;27:895\u2013901.","journal-title":"Ann Oncol."},{"key":"539_CR4","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;37:912\u201322.","journal-title":"J Clin Oncol."},{"key":"539_CR5","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl J Med. 2014;370:1008\u201318.","journal-title":"N. Engl J Med"},{"key":"539_CR6","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803\u201311.","journal-title":"J Clin Oncol."},{"key":"539_CR7","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.","journal-title":"Leukemia."},{"key":"539_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803\u20139.","journal-title":"Nat Struct Mol Biol."},{"key":"539_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164:811\u201321.","journal-title":"Br J Haematol"},{"key":"539_CR10","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713\u201320.","journal-title":"Blood."},{"key":"539_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.15797","volume":"185","author":"H Chiu","year":"2019","unstructured":"Chiu H, Trisal P, Bjorklund C, Carrancio S, Tora\u00f1o EG. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. Br J Haematol. 2019;185:240\u201353.","journal-title":"Br J Haematol."},{"key":"539_CR12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent Lymphoma. J Clin Oncol. 2019;37:1188\u201399.","journal-title":"J Clin Oncol."},{"key":"539_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/bjh.12755","volume":"165","author":"JM Tuscano","year":"2014","unstructured":"Tuscano JM, Dutia M, Chee K. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165:375\u201381.","journal-title":"Br J Haematol"},{"key":"539_CR14","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","volume":"33","author":"JP Leonard","year":"2015","unstructured":"Leonard JP, Jung SH, Johnson J, Pitcher BN, Bartlett NL. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635\u201340.","journal-title":"J Clin Oncol."},{"key":"539_CR15","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.3324\/haematol.2015.139329","volume":"101","author":"S Sacchi","year":"2016","unstructured":"Sacchi S, Marcheselli R, Bari A, Buda G, Molinari AL, Baldini L, et al. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica. 2016;101:e196\u2013199.","journal-title":"Haematologica."},{"key":"539_CR16","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.1200\/JCO.2020.38.15_suppl.8046","volume":"38","author":"D Andorsky","year":"2020","unstructured":"Andorsky D, Coleman M, Yacoub A. MAGNIFY Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory NHL. J Clin Oncol. 2020;38:8046.","journal-title":"J Clin Oncol."},{"key":"539_CR17","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser FA, Cartron G, Thieblemont C, Solal-C\u00e9ligny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912\u20139.","journal-title":"J Clin Oncol."},{"key":"539_CR18","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6:e429\u201337.","journal-title":"Lancet Haematol"},{"key":"539_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","volume":"24","author":"P Am\u00e9-Thomas","year":"2014","unstructured":"Am\u00e9-Thomas P, Tarte K. The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. Semin Cancer Biol. 2014;24:23\u201332.","journal-title":"Semin Cancer Biol."},{"key":"539_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.hoc.2020.02.007","volume":"34","author":"L Ysebaert","year":"2020","unstructured":"Ysebaert L, Morschhauser F. Immunomodulatory agents in follicular lymphoma. Hematol Oncol Clin North Am. 2020;34:715\u201326.","journal-title":"Hematol Oncol Clin North Am."},{"key":"539_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","volume":"121","author":"JH Myklebust","year":"2013","unstructured":"Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013;121:1367\u201376.","journal-title":"Blood."},{"key":"539_CR22","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","volume":"9","author":"T Jelinek","year":"2018","unstructured":"Jelinek T, Paiva B, Hajek R. Update on PD-1\/PD-L1 inhibitors in multiple myeloma. Front Immunol. 2018;9:2431.","journal-title":"Front Immunol."},{"key":"539_CR23","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128:4654\u201368.","journal-title":"J Clin Invest"},{"key":"539_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06002-8","volume":"7","author":"HT Lee","year":"2017","unstructured":"Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017;7:5532.","journal-title":"Sci Rep."},{"key":"539_CR25","first-page":"67","volume":"8","author":"N Seetharamu","year":"2017","unstructured":"Seetharamu N, Preeshagul IR, Sullivan KM. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. Lung Cancer 2017;8:67\u201378.","journal-title":"Lung Cancer"},{"key":"539_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.","journal-title":"J Immunother Cancer"},{"key":"539_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hon.2437_126","volume":"35","author":"ML Palomba","year":"2017","unstructured":"Palomba ML, Till BG, Park SI. A phase Ib study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non\u2010Hodgkin lymphoma (NHL). Hematol Oncol. 2017;35:137\u20138.","journal-title":"Hematol Oncol"},{"key":"539_CR28","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol."},{"key":"539_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol."},{"key":"539_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, et al. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019;134:761\u20134.","journal-title":"Blood."},{"key":"539_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N. Engl J Med. 2018;379:934\u201347.","journal-title":"N. Engl J Med"},{"key":"539_CR32","doi-asserted-by":"publisher","first-page":"7531","DOI":"10.1200\/JCO.2017.35.15_suppl.7531","volume":"35","author":"NH Fowler","year":"2017","unstructured":"Fowler NH, Neelapu SS, Samaniego F, Forbes S, Hagemeister FB, Fayad L, et al. Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I\/II study. J Clin Oncol. 2017;35:7531.","journal-title":"J Clin Oncol."},{"key":"539_CR33","unstructured":"REVLIMID Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revlimid-epar-product-information_en.pdf Last updated January 2020. [Last accessed 6 Feb 2020]."},{"key":"539_CR34","unstructured":"FDA. GAZYVA: Highlights of Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125486s017s018lbl.pdf. Vol. 2020; 2020."},{"key":"539_CR35","unstructured":"TECENTRIQ Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf Last updated October 2019 [Last accessed 11 Feb 2020]."},{"key":"539_CR36","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","volume":"6","author":"MV Mateos","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6:e459\u201369.","journal-title":"Lancet Haematol"},{"key":"539_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","volume":"19","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018;19:325\u201333.","journal-title":"Rev Endocr Metab Disord"},{"key":"539_CR38","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","volume":"6","author":"SZ Usmani","year":"2019","unstructured":"Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6:e448\u201358.","journal-title":"Lancet Haematol"},{"key":"539_CR39","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","volume":"34","author":"C Pott","year":"2020","unstructured":"Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, et al. MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia. 2020;34:522\u201332.","journal-title":"Leukemia."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00539-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:22:28Z","timestamp":1669918948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00539-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00539-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"5 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FM reports personal fees from AbbVie, Celgene, Epizyme, F. Hoffmann-La Roche Ltd\/Genentech Inc., Gilead, Janssen and Servier. NG reports grants and personal fees from AstraZeneca, Bristol Myers Squibb, TG Therapeutics, and Pharmacyclics, personal fees from Genmab, Seattle Genetics, Janssen, Karyopharm Therapeutics, AbbVie and Gilead and grants from Genentech Inc., and Forty Seven Inc. ISL has served on advisory boards from Seattle Genetics, Janssen Scientific and Verastem Inc.; MLP has served on advisory boards for Novartis, Kite Pharma and Merck. AM reports grants from ADC Therapeutics, Affimed, Celgene\/Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Forty Seven Inc.\/Gilead, Genentech Inc., Incyte, Innate Pharma, Juno Therapeutics\/Bristol Myers Squibb, Kite Pharma\/Gilead, Miragen Therapeutics Inc., OncoTartis Inc., Seattle Genetics, Takeda, TG Therapeutics Inc., Merck and Rhizen Pharmaceuticals and personal fees from AstraZeneca, Carevive Systems Inc, Gilead, Pharmacyclics, Incyte, Kyowa Kirin, MorphoSys\/Incyte, Seattle Genetics, TG Therapeutics and Rigel Pharmaceuticals Inc.; OC reports grants from F. Hoffmann-La Roche Ltd and Gilead; personal fees and non-financial support from F. Hoffmann-La Roche Ltd, Janssen, Takeda, Bristol Myers Squibb, Amgen, AbbVie; personal fees from Gilead and Merck. DS has been an investigator for AbbVie-sponsored clinical trials. SK is an employee of IQVIA; AK and TN are employees of F. Hoffmann-La Roche Ltd. RM is an employee of Genentech Inc. and has equity ownership in F. Hoffmann-La Roche Ltd. GS reports personal fees from F. Hoffmann-La Roche Ltd, Gilead, Celgene, Janssen Pharmaceuticals, Novartis, Amgen, AbbVie, Autolus, Epizyme, MorphoSys, Takeda, Genmab, Allogene, VelosBio Inc., and BeiGene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}